Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 390.82 g/mol |
---|---|
Molecular Formula | C14H23ClN6O5 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 9 |
Exact Mass | 390.1418455 g/mol |
Monoisotopic Mass | 390.1418455 g/mol |
Topological Polar Surface Area | 167 A^2 |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 528 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Valcyte |
PubMed Health | Valganciclovir (By mouth) |
Drug Classes | Antiviral |
Drug Label | Valcyte contains valganciclovir hydrochloride (valganciclovir HCl), a hydrochloride salt of the L-valyl ester of ganciclovir that exists as a mixture of two diastereomers. Ganciclovir is a synthetic guanine derivative active against CMV.Valcyte is av... |
Active Ingredient | Valganciclovir hydrochloride |
Dosage Form | Tablet; For solution |
Route | Oral |
Strength | 50mg/ml; eq 450mg base |
Market Status | Prescription |
Company | Hoffmann La Roche |
2 of 4 | |
---|---|
Drug Name | Valganciclovir hydrochloride |
Drug Label | Valcyte contains valganciclovir hydrochloride (valganciclovir HCl), a hydrochloride salt of the L-valyl ester of ganciclovir that exists as a mixture of two diastereomers. Ganciclovir is a synthetic guanine derivative active against CMV.Valcyte is av... |
Active Ingredient | Valganciclovir hydrochloride |
Dosage Form | Tablet |
Route | oral |
Strength | 450mg |
Market Status | Tentative Approval |
Company | Ranbaxy |
3 of 4 | |
---|---|
Drug Name | Valcyte |
PubMed Health | Valganciclovir (By mouth) |
Drug Classes | Antiviral |
Drug Label | Valcyte contains valganciclovir hydrochloride (valganciclovir HCl), a hydrochloride salt of the L-valyl ester of ganciclovir that exists as a mixture of two diastereomers. Ganciclovir is a synthetic guanine derivative active against CMV.Valcyte is av... |
Active Ingredient | Valganciclovir hydrochloride |
Dosage Form | Tablet; For solution |
Route | Oral |
Strength | 50mg/ml; eq 450mg base |
Market Status | Prescription |
Company | Hoffmann La Roche |
4 of 4 | |
---|---|
Drug Name | Valganciclovir hydrochloride |
Drug Label | Valcyte contains valganciclovir hydrochloride (valganciclovir HCl), a hydrochloride salt of the L-valyl ester of ganciclovir that exists as a mixture of two diastereomers. Ganciclovir is a synthetic guanine derivative active against CMV.Valcyte is av... |
Active Ingredient | Valganciclovir hydrochloride |
Dosage Form | Tablet |
Route | oral |
Strength | 450mg |
Market Status | Tentative Approval |
Company | Ranbaxy |
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
GDUFA
DMF Review : Complete
Rev. Date : 2017-11-07
Pay. Date : 2017-04-28
DMF Number : 31546
Submission : 2017-05-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24434
Submission : 2010-12-08
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-11-16
Pay. Date : 2015-11-10
DMF Number : 26314
Submission : 2012-08-24
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-06-28
Pay. Date : 2012-12-07
DMF Number : 26079
Submission : 2012-05-23
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-09
Pay. Date : 2012-12-21
DMF Number : 23044
Submission : 2009-08-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19060
Submission : 2005-12-21
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23946
Submission : 2010-07-06
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-03-06
Pay. Date : 2012-11-06
DMF Number : 23859
Submission : 2010-05-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-02-04
Pay. Date : 2015-09-28
DMF Number : 23322
Submission : 2009-11-30
Status : Active
Type : II
Certificate Number : CEP 2023-375 - Rev 00
Status : Valid
Issue Date : 2024-12-17
Type : Chemical
Substance Number : 2930
Certificate Number : CEP 2023-414 - Rev 00
Status : Valid
Issue Date : 2025-05-02
Type : Chemical
Substance Number : 2930
Valganciclovir Hydrochloride, Site-II
Certificate Number : CEP 2024-111 - Rev 00
Status : Valid
Issue Date : 2024-04-24
Type : Chemical
Substance Number : 2930
Certificate Number : CEP 2022-398 - Rev 01
Status : Valid
Issue Date : 2025-02-26
Type : Chemical
Substance Number : 2930
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Portugal
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 450MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Portugal
Regulatory Info :
Registration Country : Italy
Brand Name : Valcyte
Dosage Form : Valganciclovir 450Mg 60 Units Oral Use
Dosage Strength : 60 cpr riv 450 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Sweden
Brand Name : Valcyte
Dosage Form : FILM COATED PILL
Dosage Strength : 450 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Valcyte
Dosage Form : FILM COATED PILL
Dosage Strength : 450 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Valcyte
Dosage Form : FILM COATED PILL
Dosage Strength : 450 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Valcyte
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 450 mg
Packaging : Box of plastic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Brand Name : VALGANCICLOVIR SANDOZ
Dosage Form : Film-Coated Tablets
Dosage Strength : 450 mg
Packaging : 60 UNITS 450 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Valganciclovir Sandoz
Dosage Form : Filmtabl
Dosage Strength : 450mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Valcyte
Dosage Form : FILM COATED PILL
Dosage Strength : 450 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Valcyte
Dosage Form : FILM COATED PILL
Dosage Strength : 450 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Related Excipient Companies
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Oral
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
Dosage Form : Suspension
Grade : Oral
Dosage Form : Suspension
Grade : Oral
Excipients by Applications
Global Sales Information
Company : Genentech, Inc.
Valganciclovir HCl
Drug Cost (USD) : 317,771
Year : 2023
Prescribers : 33
Prescriptions : 72
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : AHP
Valganciclovir HCl
Drug Cost (USD) : 19,537
Year : 2023
Prescribers : 49
Prescriptions : 67
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Actavis/Teva
Valganciclovir HCl
Drug Cost (USD) : 452,017
Year : 2023
Prescribers : 132
Prescriptions : 242
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Ajanta Pharma L
Valganciclovir HCl
Drug Cost (USD) : 7,057,546
Year : 2023
Prescribers : 7407
Prescriptions : 15204
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Aurobindo Pharm
Valganciclovir HCl
Drug Cost (USD) : 12,157,466
Year : 2023
Prescribers : 12704
Prescriptions : 29297
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Camber Pharmace
Valganciclovir HCl
Drug Cost (USD) : 16,030,820
Year : 2023
Prescribers : 17840
Prescriptions : 43666
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Cipla USA, Inc.
Valganciclovir HCl
Drug Cost (USD) : 179,618
Year : 2023
Prescribers : 125
Prescriptions : 334
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Dr.Reddy'S Lab
Valganciclovir HCl
Drug Cost (USD) : 4,612,093
Year : 2023
Prescribers : 6201
Prescriptions : 11773
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Granules Pharma
Valganciclovir HCl
Drug Cost (USD) : 842,963
Year : 2023
Prescribers : 175
Prescriptions : 386
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Major Pharmaceu
Valganciclovir HCl
Drug Cost (USD) : 82,429
Year : 2023
Prescribers : 165
Prescriptions : 216
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Ganciclovir and Valganciclovir
Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...
Currency : USD
2015 Revenue in Millions : 733
2014 Revenue in Millions : 373
Growth (%) : -49%
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2027-12-11
US Patent Number : 9642911
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 22257
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-12-11
Patent Expiration Date : 2027-12-11
US Patent Number : 8889109
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 22257
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-12-11
ANALYTICAL
ABOUT THIS PAGE
71
PharmaCompass offers a list of Valganciclovir Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Valganciclovir Hydrochloride manufacturer or Valganciclovir Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Valganciclovir Hydrochloride manufacturer or Valganciclovir Hydrochloride supplier.
PharmaCompass also assists you with knowing the Valganciclovir Hydrochloride API Price utilized in the formulation of products. Valganciclovir Hydrochloride API Price is not always fixed or binding as the Valganciclovir Hydrochloride Price is obtained through a variety of data sources. The Valganciclovir Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Valganciclovir Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Valganciclovir Hydrochloride, including repackagers and relabelers. The FDA regulates Valganciclovir Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Valganciclovir Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Valganciclovir Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Valganciclovir Hydrochloride supplier is an individual or a company that provides Valganciclovir Hydrochloride active pharmaceutical ingredient (API) or Valganciclovir Hydrochloride finished formulations upon request. The Valganciclovir Hydrochloride suppliers may include Valganciclovir Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Valganciclovir Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Valganciclovir Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Valganciclovir Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Valganciclovir Hydrochloride DMFs exist exist since differing nations have different regulations, such as Valganciclovir Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Valganciclovir Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Valganciclovir Hydrochloride USDMF includes data on Valganciclovir Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Valganciclovir Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Valganciclovir Hydrochloride suppliers with USDMF on PharmaCompass.
A Valganciclovir Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Valganciclovir Hydrochloride Certificate of Suitability (COS). The purpose of a Valganciclovir Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Valganciclovir Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Valganciclovir Hydrochloride to their clients by showing that a Valganciclovir Hydrochloride CEP has been issued for it. The manufacturer submits a Valganciclovir Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Valganciclovir Hydrochloride CEP holder for the record. Additionally, the data presented in the Valganciclovir Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Valganciclovir Hydrochloride DMF.
A Valganciclovir Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Valganciclovir Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Valganciclovir Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Valganciclovir Hydrochloride written confirmation (Valganciclovir Hydrochloride WC) is an official document issued by a regulatory agency to a Valganciclovir Hydrochloride manufacturer, verifying that the manufacturing facility of a Valganciclovir Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Valganciclovir Hydrochloride APIs or Valganciclovir Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Valganciclovir Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Valganciclovir Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Valganciclovir Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Valganciclovir Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Valganciclovir Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Valganciclovir Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Valganciclovir Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Valganciclovir Hydrochloride suppliers with NDC on PharmaCompass.
Valganciclovir Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Valganciclovir Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Valganciclovir Hydrochloride GMP manufacturer or Valganciclovir Hydrochloride GMP API supplier for your needs.
A Valganciclovir Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Valganciclovir Hydrochloride's compliance with Valganciclovir Hydrochloride specifications and serves as a tool for batch-level quality control.
Valganciclovir Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Valganciclovir Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Valganciclovir Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Valganciclovir Hydrochloride EP), Valganciclovir Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Valganciclovir Hydrochloride USP).